While the traditional Sanger sequencing only captures substitutions and small insertions and deletions, next-gen sequencing captures a wider range of substitutions, insertions, and deletions of DNA, as well as rearrangements such as inversions and translocations. Instead of only being able to investigate genes that we already know about, NGS allows us to discover brand new mutations and disease-causing genes.
NGS technology is even helping researchers define the genomes of pathogens that may contain details about drug sensitivities, and has been used to track outbreaks. It is completely changing the way researchers approach problems, uncovering exciting, unprecedented solutions.
Psomagen: On the Cutting Edge of NGS Technology
Taking advantage of NGS requires some extra computer capacity and the expertise to be able to understand all the new data acquired. Clinics may not have the resources, but we do.
For more than 20 years, Psomagen Inc. has provided a wide variety of genetic technology services to more than 100 countries.
Macrogen, Inc. was founded in 1997, and in 2005, Macrogen Corp. in the US was established. In 2012, Macrogen Corp. was established to provide advanced clinical sequencing services to U.S. patients and hospitals. During this time, we’ve become a leading bioscience research firm and our reputation in the industry is proof of our commitment to advanced human genomic sequencing. In 2019, the name was changed so Psomagen, Inc. to better represent the vision of the company.
As a CLIA-licensed research facility, we offer highly specialized sequencing services, utilizing the latest the latest next-generation sequencing. Additionally, the Psomagen team employs highly trained researchers who are the experts in their fields. Our next-generation sequencing services have been utilized by researchers from many prestigious institutions, including but not limited to: National Institute of Health (NIH), Food and Drug Administration (FDA), Stanford University, etc.